Group 1 - Siga Technologies Inc. (SIGA) closed at $5.83, reflecting a +0.87% change from the previous session, outperforming the S&P 500's daily gain of 0.72% [1] - Over the past month, Siga's shares have decreased by 9.69%, underperforming the Medical sector's gain of 4.51% and the S&P 500's gain of 1.02% [1] Group 2 - The upcoming earnings release of Siga Technologies Inc. is highly anticipated by investors, with a focus on recent adjustments to analyst estimates, which indicate short-term business trends [2] - Upward revisions in analyst estimates suggest positive sentiment regarding Siga's business operations and profit generation capabilities [2][3] Group 3 - Siga Technologies Inc. currently holds a Zacks Rank of 3 (Hold), with no change in the Zacks Consensus EPS estimate over the past month [4] - The Zacks Rank system has a strong track record, with 1 stocks averaging an annual return of +25% since 1988 [4] Group 4 - Siga Technologies Inc. has a Forward P/E ratio of 4.62, significantly lower than the industry average Forward P/E of 20.11, indicating that Siga is trading at a discount compared to its peers [5] - The Medical - Drugs industry, which includes Siga, has a Zacks Industry Rank of 83, placing it in the top 34% of over 250 industries [5][6]

Company Performance - Siga Technologies Inc. closed at $6.34, reflecting a -1.71% change from the previous session, underperforming the S&P 500's loss of 1.46% [1] - The stock has increased by 8.77% over the last month, outperforming the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08% [1] Analyst Insights - Analysts and investors are closely monitoring Siga Technologies Inc. for its upcoming earnings disclosure and any revisions to analyst forecasts, which indicate short-term business trends [2] - Positive revisions in estimates suggest analyst optimism regarding the company's business and profitability [2] Valuation Metrics - Siga Technologies Inc. is currently trading with a Forward P/E ratio of 5.16, significantly lower than the industry's average Forward P/E of 20.73 [5] - The Medical - Drugs industry, which includes Siga Technologies Inc., has a Zacks Industry Rank of 92, placing it in the top 37% of over 250 industries [5] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 rated stocks producing an average annual return of +25% since 1988 [4] - Siga Technologies Inc. currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate remaining steady over the past month [4]

Company Performance - Siga Technologies Inc. closed at $6.35, with a daily increase of +0.32%, underperforming the S&P 500's gain of 1.83% [1] - Over the past month, Siga's shares appreciated by 3.94%, outperforming the Medical sector's decline of 3.48% and the S&P 500's decline of 3.31% [1] Analyst Estimates - Analysts and investors are closely monitoring Siga Technologies Inc. ahead of its upcoming earnings disclosure, with a focus on any changes in analyst estimates [2] - Upward revisions in estimates indicate analysts' positive outlook on the company's business operations and profit generation capabilities [2] Zacks Rank and Valuation - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently places Siga Technologies Inc. at 3 (Hold) [4] - Siga Technologies Inc. has a Forward P/E ratio of 5.06, which is a discount compared to the industry's average Forward P/E of 17.59 [5] - The Medical - Drugs industry, to which Siga belongs, has a Zacks Industry Rank of 70, placing it in the top 28% of over 250 industries [5]

Group 1 - Siga Technologies Inc. (SIGA) is a notable stock in the Medical sector, currently outperforming the sector with a year-to-date return of approximately 15.5% compared to the sector average of 0.3% [4] - The Zacks Rank for Siga Technologies Inc. is 2 (Buy), indicating a favorable outlook based on earnings estimate revisions and improving earnings outlooks [3] - The Zacks Consensus Estimate for SIGA's full-year earnings has increased by 3% over the past quarter, reflecting stronger analyst sentiment [4] Group 2 - Siga Technologies Inc. is part of the Medical - Drugs industry, which consists of 172 companies and is currently ranked 71 in the Zacks Industry Rank; this industry has seen an average loss of 4% year-to-date [6] - Another stock in the Medical sector, AnaptysBio, Inc. (ANAB), has a year-to-date return of 7.8% and a Zacks Rank of 2 (Buy), with its consensus EPS estimate increasing by 11.9% over the past three months [5][6] - The Medical - Biomedical and Genetics industry, to which AnaptysBio belongs, has a current ranking of 63 and has experienced a year-to-date decline of 6.6% [6]

Group 1 - The article discusses the author's extensive background in life sciences, specifically in the research and development of novel Cell & Gene Therapies (CGT) for various clinical needs, including orthopaedics and rare diseases [1] - The author emphasizes the importance of utilizing their expertise to assess the potential of novel treatments and their capacity to drive shareholder returns [1] - The focus of the analysis will be on biotechnology, pharmaceutical, Medtech, and healthcare stocks, providing insights into the companies within these sectors [1]

I’m a stock analyst with an MBA and a background in healthcare, bringing years of experience as a Registered Nurse dedicated to patient care. I've had the privilege of sharing my insights on Seeking Alpha since 2017. I am most interested in identifying underlying assumptions in stock valuations by emphasizing financial modeling techniques like DCF analysis. I then provide scenario-based forecasts to help readers gauge reasonable outcomes. I am influenced by books like Superforecasting and Antifragile. As su ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental a ...

SIGA Technologies, Inc. (NASDAQ:SIGA) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Diem Nguyen - CEO Dan Luckshire - CFO Conference Call Participants Jyoti Prakash - Edison Group Operator Good afternoon, ladies and gentlemen, and welcome to the SIGA Technologies Third Quarter 2024 Earnings Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2024 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) (Stat ...

Exhibit 99.1 SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024 • Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectively • Received $122 Million of Procurement Orders from the U.S. Government in the Third Quarter • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three a ...